✦ LIBER ✦

Endocrine versus endocrine plus five-drug chemotherapy in postmenopausal women with stage II estrogen receptor-positive breast cancer

✍ Scribed by Olof H. Pearson; Charles A. Hubay; Nahida H. Gordon; James S. Marshall; Joseph P. Crowe; Baha'Uddin M. Arafah; William McGuire

Publisher: John Wiley and Sons
Year: 1989
Tongue: English
Weight: 446 KB
Volume: 64
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19891101)64:9<1819::aid-cncr2820640910>3.0.co;2-n

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase 2 randomized trial of primary endo

Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer

✍ Vladimir F. Semiglazov; Vladislav V. Semiglazov; Garik A. Dashyan; Elena K. Zilt 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 194 KB

## Abstract ## BACKGROUND. Few studies have compared primary neoadjuvant endocrine therapy with neoadjuvant chemotherapy in breast cancer patients. The need for preoperative chemotherapy with doxorubicin or taxanes may be reduced in postmenopausal patients with estrogen receptor (ER)‐positive and/

Exemestane versus anastrozole as front-l

Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer : Final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial

✍ Antonio Llombart-Cussac; Amparo Ruiz; Antonio Antón; Agustí Barnadas; Silvia Ant 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 193 KB 👁 2 views